Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advance Medical Research

Neither a doctor nor a teaching hospital

Research payments

$2,076,038

35 payments

Through program year 2025, Advance Medical Research is reported as receiving $2,076,038 in research payments, across 35 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $836,077 11
2024 Research $156,754 2
2022 Research $95,288 4
2021 Research $409,705 5
2020 Research $187,980 7
2019 Research $390,234 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $956,034 3 payments
  2. Amgen Inc. $803,036 14 payments
  3. AstraZeneca Pharmaceuticals LP $298,748 7 payments
  4. Pfizer Inc. $12,685 8 payments
  5. Novartis Pharmaceuticals Corporation $5,535 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $807,033 2 payments
  2. FOURIER OLE (Ph 4) $562,429 10 payments
  3. AMETHYST Congestive Heart Failure CHF Heart Failure Therapy Area Cardiovascular, Renal and Metabolism $262,985 4 payments
  4. 20160250-FOURIER OLE (Ph 4) $204,419 2 payments
  5. Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $149,001 1 payment
  6. 20130295-FOURIER OLE (Ph 4) $36,188 2 payments
  7. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $24,112 2 payments
  8. Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Beta2 Agonist BORA $11,651 1 payment
  9. An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07248144 Plus Fulvestrant Compared to Investigators Choice of Therapy in Adult Participants With Hormone Receptorpositive Her2negative Advancedmetastatic Breast Cancer Whose Disease Progressed After Prior Cdk46 Inhibitorbased Therapy $10,645 4 payments
  10. Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $5,535 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record